治験レーダーAI | ||
|---|---|---|
治験 NCT05708274（対象：脊髄損傷）は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
治験(臨床試験)の詳細は主に英語で提供されています。しかし、治験レーダーAIが支援できます！「治験を説明」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT05708274 は 脊髄損傷 に関する 治療 の研究で、第I相・第一段階 介入研究 臨床試験 です。現在は 募集中 で、2023年1月20日 から開始しています。28 名の参加者 の募集が計画されています。この治験は Bronx VA Medical Center によって主催され、2025年7月30日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2024年8月6日 です。
概要
The purpose of this study is to investigate the short-term effects of 3 approved FDA drugs (cyproheptadine (CPH), carbidopa-levodopa (CD-LD), and atomoxetine (ATX)) on motor responses when delivered in combination with hand training exercises in people with chronic spinal cord injury. The goal is to learn how to better strengthen connections between the brain and spinal cord after spinal cord injury, and if this connection is improved by one(or more) of the drugs. Multiple aspects of nerve transmission and muscle response will be measured via noninvasive brain and spinal cord stimulation, along with motor performance (dexterity and strength).
詳細説明
Research will take place at the James J. Peters VA Medical Center (JJPVAMC), Bronx, NY. There are seven visits in total, including an initial evaluation and clinical assessment session. Each visit will last roughly 5 hours or less. We plan to enroll 28 participants with spinal cord injury over a two-year period.
The study is designed as a double-blind, placebo-controlled, single-dose, randomized crossover investigation involving four study drug visits (CPH, CD-LD, ATX, or placebo).
The same participants will partake in all four interventions in randomized order with at least 1-week washout representative of greater than 5x drug half-life; to avoid accumulative effects. To reduce potential learning effects from motor training and task-related outcome measurements, participants will partake in two motor training practice sessions prior to commencing the experiments for task familiarity.
This study will consist of electromyography (surface recordings of muscle activity), peripheral nerve stimulation, transcranial magnetic brain stimulation (TMS), and transcutaneous electrical spinal cord stimulation (TSCS), targeting the hand/arm muscles.
Though it is unlikely given the single-dose nature, participants may experience side effects following drug administration. Prior to consenting, all volunteers will undergo a comprehensive pre-screening evaluation including blood tests to ensure there are no contraindications.
Please note, there is no expectation of long-term benefit from this study.
公式タイトル
The Role of Pharmacological Agents in Restoring Neuronal Excitability After Chronic Spinal Cord Injury (SCI)
疾患／病気
脊髄損傷その他の研究識別子
- JJPVAMC IRB 1685818
NCT番号
開始日
2023-01-20
最終更新日
2024-08-06
終了予定日
2025-07-30
目標参加者数
28
試験の種類
介入研究
治験の相・段階
第I相・第一段階
状況
募集中
キーワード
Transcranial magnetic stimulation
Pharmacological agents
Transcutaneous spinal cord stimulation
Hand exercise
Pharmacological agents
Transcutaneous spinal cord stimulation
Hand exercise
主目的
治療
割付方法
無作為化
介入モデル
交叉・クロスオーバー
盲検化
二重盲検
群（アーム）／介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
実験的CPH + hand training A single dose of Cyproheptadine (CPH) (8 mg) will be administered. Supplied as 2 over-encapsulated pills of 4 mg each. | CPH + Hand Training Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements. |
実験的CD-LD + hand training A single dose of IR Carbidopa-levodopa (CD-LD) (50/200 mg) will be administered. Supplied as 2 over-encapsulated pills (25 mg carbidopa / 100 mg levodopa each). | CD-LD + Hand Training Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements. |
実験的ATX + hand training A single dose of Atomoxetine (ATX) (40 mg) will be administered. Supplied as 1 over-encapsulated pill of 40 mg plus 1 placebo capsule. | ATX + Hand Training Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements. |
プラセボ対照薬Placebo + hand training A single dose of Placebo will be administered. Supplied as 2 gelatin capsules, identical in number, size, shape and color, filled with microcrystalline cellulose. | Placebo + Hand Training Following a 10-minute rest after baseline measurements a single dose pharmacological agent or placebo will be administered, in blinded fashion, with up to 180 mL of noncarbonated water, on an empty stomach (minimum 2 hours without food). After capsule ingestion, participants will spend 50 minutes performing hand task-oriented training, resting for 10 minutes before undertaking post-intervention outcome measurements. |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Assessing task performance (dexterity) | Unilateral manual dexterity will be assessed using the 9-Hole Peg Test (Aim 1a). | Assess change from baseline to 10 minutes after completion of drug+task training. |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Assessing task performance (dexterity) | Unilateral manual dexterity will be assessed using the Box and Block Test (Aim 1a). | Assess change from baseline to 10 minutes after completion of drug+task training. |
Assessing volitional grip strength | Maximal grip force will be measured (Aim 1b). The attempt with the highest value will be used for analysis. | Assess change from baseline to 10 minutes after completion of drug+task training. |
Assessing volitional pinch strength | Maximal pinch force will be measured (Aim 1b). The attempt with the highest value will be used for analysis. | Assess change from baseline to 10 minutes after completion of drug+task training. |
Assessing corticospinal plasticity | Corticospinal plasticity will be measured via single-pulse TMS recruitment curves (Aim 2a). | Assess change from baseline to 10 minutes after completion of drug+task training. |
Assessing cortical plasticity | Short intracortical inhibition (SICI) and intracortical facilitation (ICF) will be evoked with paired-pulse TMS at various interstimulus intervals according to the methods previously employed (Murray \& Knikou, 2017). | Assess change from baseline to 10 minutes after completion of drug+task training. |
Assessing spinal plasticity | Spinal plasticity will be measured via single-pulse TSCS recruitment curves (Aim 2b). | Assess change from baseline to 10 minutes after completion of drug+task training. |
Tracking cardiovascular responses (heart rate) | Observed measures of heart rate (HR) (Aim 3a) will be monitored throughout. | Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline. |
Tracking cardiovascular responses (blood oxygen saturation) | Observed measures of blood oxygen saturation (SpO2) (Aim 3a) will be monitored throughout. | Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline. |
Tracking cardiovascular responses (blood pressure) | Observed measures of blood pressure (BP) (Aim 3a) will be monitored throughout. | Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline. |
Tracking symptoms | Participant-reported safety questionnaire (Aim 3b) will be monitored for any symptoms felt throughout the study. | Measured every 5-10 minutes, for up to 4 hours. Change will be compared to baseline. |
Tracking side effects (drug administration) | Adverse event (AE) questionnaire (Aim 3b) related to any participant-reported experience following drug administration. | Assess change from end of day 1 testing to 24 hours after study completion. |
Tracking side effects (study testing stimulation) | Adverse event (AE) questionnaire (Aim 3b) related to any participant-reported experience following brain and/or spinal stimulation received during the experiment. | Assess change from end of day 1 testing to 24 hours after study completion. |
適格基準
対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て
- Male or female between 18 and 65 years of age; clinically stable chronic (> 12 months) SCI at or above C8 spinal segment;
- Motor-incomplete with a score of 2 or more (out of 5) on manual muscle testing (MMT) of finger extension, finger flexion, or finger abduction in left or right hand(s); or able to perform thumb-index finger pinch of the left or right hand;
- Detectable stimulation-evoked muscle responses of the left or right first dorsal interosseous (FDI) and/or abductor pollicis brevis (APB); Detectable FDI/APB surface electromyography (EMG) muscle activity during thumb-index finger pinch;
- Must have stable: medication [≥ 30 days prior]; rehabilitation regimen [≥ 15 days prior];
- Must be able to: abstain from alcohol, smoking and caffeine consumption on the day prior/of each experiment; abstain from recreational drugs for the entirety of the study; commit to study requirements (i.e., 7 visits); provide informed consent.
- History of moderate or severe head trauma (loss of consciousness for greater than one hour or evidence of brain contusion or hemorrhage or depressed skull fracture on prior imaging);
- History of other serious central or peripheral neurological injury;
- History of implanted brain/spine/nerve stimulators, aneurysm clips, ferromagnetic metallic implants in the head (except inside mouth); cochlear implants; cardiac pacemaker/defibrillator; intracardiac lines; currently increased intracranial pressure; or other contraindications to brain stimulation or task performance;
- Ventilator dependence or patent tracheostomy site;
- Unstable syrinx, or multiple spinal cord lesions;
- Unclear diagnosis; History of stroke, brain tumor, brain abscess, or multiple sclerosis;
- Personal history of seizures; extensive family history of seizures; use of medications that lower seizure threshold (e.g., amphetamines, dalfampridine, and bupropion);
- Use of the study medications; Use of medications known to have significant adverse interactions with the study medication as described in the manufacturers' prescribing information [14 days prior]; previous allergic reaction or hypersensitivity to study drug(s);
- Presence of a medical condition that represents a risk for study drug(s) administration; evidence of liver disease or clinical jaundice; neutropenia; glaucoma; gastrointestinal ulcer(s); active malignancy; undiagnosed skin lesions; autoimmune disorders; chronic infectious diseases (e.g. HIV, hepatitis B or C); pregnancy or nursing mothers (a pregnancy urine test may be warranted); neurologic disorders (including a history of serious head trauma or seizures), and uncontrolled cardiovascular, metabolic, pulmonary or renal disease; premorbid, ongoing major depression or psychosis, altered cognitive status; bipolar disorder; suicidal ideation or past suicide attempts;
- History of severe hearing problems, loss or tinnitus;
- Presence of urinary infection, fever, pressure ulcer; or open skin lesions (shoulders or arms);
- Recent history (< 6 months) of recurrent autonomic dysreflexia, defined as a syndrome of sudden rise in systolic pressure greater than 20 mm Hg or diastolic pressure greater than 10 mm Hg, without rise in HR, accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, and blurry vision (closely monitored during all testing procedures);
- Heavy alcohol consumption (greater than equivalent of 5 oz of liquor) within previous 48 hours;
- Recent history (>1 year) of chemical substance dependency or significant psychosocial disturbance;
- Study participation of an investigational drug or device [60 days prior];
- Unsuitable for study participation as determined by the study physician.
Bronx VA Medical Center責任者
Lynda M. Murray, 研究責任者, Assistant Professor, Bronx VA Medical Center
試験中央連絡先
連絡先: Caitlyn "Sig" N Sigafose, BS, 718-584-9000, [email protected]
連絡先: Francisco E Castano, MPH, 718-584-9000, [email protected]
1 1カ国の場所
New York
James J. Peters Veterans Affairs Medical Center, The Bronx, New York, 10468, United States
Lynda M Murray, PhD, 連絡先, 718-584-9000, [email protected]
募集中